Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR‑140‑5p expression

Wu,Linsheng; Li,Haoxia; Chen,Shengyou; Wu,Xiaoqiang; Chen,Xiaomin; Wang,Fangping

doi:10.3892/mmr.2020.11667

Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR‑140‑5p expression

Authors:
- Linsheng Wu
- Haoxia Li
- Shengyou Chen
- Xiaoqiang Wu
- Xiaomin Chen
- Fangping Wang
View Affiliations

Affiliations: Department of Geriatric Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310000, P.R. China, Department of Hepatobiliary Surgery, The People's Hospital of Xinchang, Shaoxing, Zhejiang 312500, P.R. China
Published online on: November 4, 2020 https://doi.org/10.3892/mmr.2020.11667
Article Number: 29
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a frequent malignant tumor. Catalpol is a Chinese medicine extract with a number of pharmacologically active properties. The present study aimed to investigate the effects and mechanisms of catalpol in HCC. HCC cells were treated with catalpol in the presence or absence of microRNA (miR)‑140‑5p inhibitor, and assays to determine cell viability, proliferation, invasion and migration were performed. Reverse transcription‑quantitative PCR and western blotting were performed to determine the mRNA and protein expression levels of miR‑140‑5p, vimentin, N‑Cadherin and E‑Cadherin. Moreover, cells were treated with catalpol in the absence or presence of transforming growth factor (TGF)‑β1, and the cell morphology was observed under a microscope. The results demonstrated that catalpol inhibited cell proliferation, invasion and migration, and decreased the expression levels of vimentin and N‑cadherin, but increased the expression levels of E‑cadherin and miR‑140‑5p. Catalpol inhibited morphological changes in epithelial‑mesenchymal transformation (EMT) of cells induced by TGF‑β1. Following inhibition of miR‑140‑5p expression, the proliferation, invasion and migration of HCC cells were promoted, E‑cadherin expression was decreased, and the levels of vimentin and N‑cadherin were increased. The miR‑140‑5p inhibitor effectively reversed the inhibitory effect of catalpol on cell proliferation, invasion and migration. Thus, the results suggested that the antitumor potential of catalpol in HCC may be exerted by regulating the expression of miR‑140‑5p to inhibit proliferation, invasion, migration and EMT of HCC cells.

View Figures

View References

1	Intaraprasong P, Siramolpiwat S and Vilaichone RK: Advances in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 17:3697–3703. 2016.PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Sakamoto M: Pathology of early hepatocellular carcinoma. Hepatol Res. 37 (Suppl 2):S135–S138. 2007. View Article : Google Scholar : PubMed/NCBI
4	Wei PL, Huang CY and Chang YJ: Propyl gallate inhibits hepatocellular carcinoma cell growth through the induction of ROS and the activation of autophagy. PLoS One. 14:e02105132019. View Article : Google Scholar : PubMed/NCBI
5	Deng GL, Zeng S and Shen H: Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
6	Fang F, Yang L, Tao Y and Qin W: FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo. Cancer. 118:134–146. 2012. View Article : Google Scholar : PubMed/NCBI
7	Moriguchi M, Umemura A and Itoh Y: Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol. 9:184–190. 2016. View Article : Google Scholar : PubMed/NCBI
8	Clark T, Maximin S, Meier J, Pokharel S and Bhargava P: Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 44:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
9	Xu J: Trends in liver cancer mortality among adults aged 25 and over in the United States, 2000–2016. NCHS Data Brief. 1–8. 2018.
10	Liao CY, Lee CC, Tsai CC, Hsueh CW, Wang CC, Chen IH, Tsai MK, Liu MY, Hsieh AT, Su KJ, et al: Novel investigations of flavonoids as chemopreventive agents for hepatocellular carcinoma. Biomed Res Int. 2015:8405422015. View Article : Google Scholar : PubMed/NCBI
11	Liu C, Ma R, Wang L, Zhu R, Liu H, Guo Y, Zhao B, Zhao S, Tang J, Li Y, et al: Rehmanniae radix in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology. J Ethnopharmacol. 198:351–362. 2017. View Article : Google Scholar : PubMed/NCBI
12	Kim SH, Yook TH and Kim JU: Rehmanniae radix, an effective treatment for patients with various inflammatory and metabolic diseases: Results from a review of Korean publications. J Pharmacopuncture. 20:81–88. 2017.PubMed/NCBI
13	Lee B, Shim I, Lee H and Hahm DH: Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. J Microbiol Biotechnol. 21:874–883. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yuan CX, Chu T, Liu L, Li HW, Wang YJ, Guo AC and Fan YP: Catalpol induces oligodendrocyte precursor cell-mediated remyelination in vitro. Am J Transl Res. 7:2474–2481. 2015.PubMed/NCBI
15	Liu YR, Lei RY, Wang CE, Zhang BA, Lu H, Zhu HC and Zhang GB: Effects of catalpol on ATPase and amino acids in gerbils with cerebral ischemia/reperfusion injury. Neurol Sci. 35:1229–1233. 2014. View Article : Google Scholar : PubMed/NCBI
16	Li MY, Cheng XR, Zhou WX and Zhang YX: The effects of catalpol on Alzheimer's disease: Research advances. Journal of International Pharmaceutical Research. 43:199–204. 2016.
17	Zhu J, Chen X, Wang H and Yan Q: Catalpol protects mice against renal ischemia/reperfusion injury via suppressing PI3K/Akt-eNOS signaling and inflammation. Int J Clin Exp Med. 8:2038–2044. 2015.PubMed/NCBI
18	Zhang X, Zhang A, Jiang B, Bao Y, Wang J and An L: Further pharmacological evidence of the neuroprotective effect of catalpol from rehmannia glutinosa. Phytomedicine. 15:484–490. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhu P, Wu Y, Yang A, Fu X, Mao M and Liu Z: Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis. Biomed Pharmacother. 95:68–76. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liu C, Wu F, Liu Y and Meng C: Catalpol suppresses proliferation and facilitates apoptosis of MCF-7 breast cancer cells through upregulating microRNA-146a and downregulating matrix metalloproteinase-16 expression. Mol Med Rep. 12:7609–7614. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wang ZH and Sheng HZ: Catalpol inhibits migration and induces apoptosis in gastric cancer cells and in athymic nude mice. Biomed Pharmacother. 103:1708–1719. 2018. View Article : Google Scholar : PubMed/NCBI
22	Adams BD, Kasinski AL and Slack FJ: Aberrant regulation and function of microRNAs in cancer. Curr Biol. 24:R762–R776. 2014. View Article : Google Scholar : PubMed/NCBI
23	Seven M, Karatas OF, Duz MB and Ozen M: The role of miRNAs in cancer: From pathogenesis to therapeutic implications. Future Oncol. 10:1027–1048. 2014. View Article : Google Scholar : PubMed/NCBI
24	Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y, Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI
25	Zhai H, Fesler A, Ba Y, Wu S and Ju J: Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget. 6:19735–19746. 2015. View Article : Google Scholar : PubMed/NCBI
26	Lan H, Chen W, He G and Yang S: miR-140-5p inhibits ovarian cancer growth partially by repression of PDGFRA. Biomed Pharmacother. 75:117–122. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yan X, Zhu Z, Xu S, Yang LN, Liao XH, Zheng M, Yang D, Wang J, Chen D, Wang L, et al: MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways. Sci Rep. 7:459152017. View Article : Google Scholar : PubMed/NCBI
28	Li C, Zhou D, Hong H, Yang S, Zhang L, Li S, Hu P, Ren H, Mei Z and Tang H: TGFβ1-miR-140-5p axis mediated up-regulation of Flap endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Aging (Albany NY). 11:5593–5612. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zou G, Zhong W, Wu F, Wang X and Liu L: Catalpol attenuates cardiomyocyte apoptosis in diabetic cardiomyopathy via Neat1/miR-140-5p/HDAC4 axis. Biochimie. 165:90–99. 2019. View Article : Google Scholar : PubMed/NCBI
30	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. ELife. 4:e050052015. View Article : Google Scholar
31	Rao X, Huang X, Zhou Z and Lin X: An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
32	Mikaelian I, Malek M, Gadet R, Viallet J, Garcia A, Girard-Gagnepain A, Hesling C, Gillet G, Gonzalo P, Rimokh R and Billaud M: Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism. Cancer Res. 73:6621–6631. 2013. View Article : Google Scholar : PubMed/NCBI
33	Gheldof A and Berx G: Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
34	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
35	Villanueva A: Hepatocellular carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
36	Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al: Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 109:djx0302017. View Article : Google Scholar
37	Liang D, Xue H, Yu Y, Lv F, You W and Zhang B: Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 8:9416–9421. 2015.PubMed/NCBI
38	Reig M, da Fonseca LG and Faivre S: New trials and results in systemic treatment of HCC. J Hepatol. 69:525–533. 2018. View Article : Google Scholar : PubMed/NCBI
39	Bai Y, Zhu R, Tian Y, Li R, Chen B, Zhang H, Xia B, Zhao D, Mo F, Zhang D and Gao S: Catalpol in diabetes and its complications: A review of pharmacology, pharmacokinetics, and safety. Molecules. 24:33022019. View Article : Google Scholar
40	Lu J, Wang Y, Zhao W, Li N, Li H, Lu J, Zeng W, Bao S and Bai Y: Effects of catalpol, L-shikonin and paeonol extracted from radix rehmanniae, radix arnebiae and cortex moutan on KGF-induced HaCaT cell proliferation. Zhonghua Yi Xue Za Zhi. 94:1265–1269. 2014.(In Chinese). PubMed/NCBI
41	Wang JH, Zou L, Wan D, Huifeng Z, Wang Y and Qin L: Review of catalpol's pleiotropic signaling pathways. Chin Pharmacol Bull. 31:1189–1194. 2015.
42	Wan D, Xue L, Zhu H and Luo Y: Catalpol induces neuroprotection and prevents memory dysfunction through the cholinergic system and BDNF. Evid Based Complement Alternat Med. 2013:1348522013. View Article : Google Scholar : PubMed/NCBI
43	Zhou J, Xu G, Ma S, Li F, Yuan M, Xu H and Huang K: Catalpol ameliorates high-fat diet-induced insulin resistance and adipose tissue inflammation by suppressing the JNK and NF-κB pathways. Biochem Biophys Res Commun. 467:853–858. 2015. View Article : Google Scholar : PubMed/NCBI
44	Cai Z, Xu K, Li Y, Lv Y, Bao J and Qiao L: Long noncoding RNA in liver cancer stem cells. Discov Med. 24:87–93. 2017.PubMed/NCBI
45	Yang JY, Li D, Zhang Y, Guan BX, Gao P, Zhou XC and Zhou CJ: The expression of MCM7 is a useful biomarker in the early diagnostic of gastric cancer. Pathol Oncol Res. 24:367–372. 2018. View Article : Google Scholar : PubMed/NCBI
46	Jin D, Cao M, Mu X, Yang G, Xue W, Huang Y and Chen H: Catalpol inhibited the proliferation of T24 human bladder cancer cells by inducing apoptosis through the blockade of Akt-mediated anti-apoptotic signaling. Cell Biochem Biophys. 71:1349–1356. 2015. View Article : Google Scholar : PubMed/NCBI
47	Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012. View Article : Google Scholar : PubMed/NCBI
48	Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
49	De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
50	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
51	Wang L and Xue GB: Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis. Biochem Biophys Res Commun. 495:27–34. 2018. View Article : Google Scholar : PubMed/NCBI
52	Wu J, Zhang T, Chen Y and Ha S: MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression. Biosci Rep. 40:BSR201932952020. View Article : Google Scholar : PubMed/NCBI
53	Wang Y, Zhang P, Yuan M and Li X: Overexpression of miRNA-21 promotes the proliferation and invasion in hepatocellular carcinoma cells via suppressing SMAD7. Technol Cancer Res Treat. 18:15330338198786862019. View Article : Google Scholar : PubMed/NCBI
54	Kong Q, Liang C, Jin Y, Pan Y, Tong D, Kong Q and Zhou J: The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a. Cell Mol Biol Lett. 24:262019. View Article : Google Scholar : PubMed/NCBI
55	Lv J, Fan HX, Zhao XP, Lv P, Fan JY, Zhang Y, Liu M and Tang H: Long non-coding RNA Unigene56159 promotes epithelial-mesenchymal transition by acting as a ceRNA of miR-140-5p in hepatocellular carcinoma cells. Cancer Lett. 382:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
56	Zhao L, Wang Y and Liu Q: Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma. Exp Mol Pathol. 109:51–60. 2019. View Article : Google Scholar : PubMed/NCBI